Donnie Hardison

Laboratory Corp. of America Holdings operates as a life sciences company, which engages in the provision of vital information to help health professionals make clear and confident decisions. It operates through the Drug Development and Diagnostics segments. The Drug Development segment consists of lead optimization, preclinical safety assessment, analytical services, clinical trials, central laboratories, biomarkers, and companion diagnostics, market access, and technology solutions. The Diagnostics segment includes primary care, women's health, specialty medicine, oncology, ACOs, and hospitals and health systems. The company was founded in 1971 and is headquartered in Burlington, NC.

Good Start Genetics, Inc. operates as a molecular diagnostics firm. It offers pre-pregnancy diagnostic test services to screen a panel of genetic disorders. The firm also provides clinical laboratory and genetic counseling support services. The company was founded by Eric Boutin, Paris Wallace, and Gregory J. Porreca in December 2007 and is headquartered in Cambridge, MA.

Predictive Biosciences is a fully-integrated developer of novel molecular diagnostic cancer assays, and a subspecialty, urology-focused provider of anatomic pathology laboratory products and services. The Company pioneered the Clinical Intervention Determining Diagnostic (CIDD) and Multi-Analyte Diagnostic Readout (MADR) approaches to cancer management, leveraging its portfolio of patented biomarkers and clinical algorithms. Based on these approaches, the Company is building a unique portfolio of assays that enable physicians to reliably determine the presence or absence of cancer with very high levels of confidence. Predictive Biosciences' first tests are targeted toward the growing bladder cancer and prostate cancer survivor populations and the large number of individuals undergoing clinical workups for these malignancies. Predictive Biosciences' corporate headquarters and innovation center is located in Lexington, Massachusetts. The Company's commercial division, OncoDiagnostic Laboratory (ODL), is located in Cleveland, Ohio. ODL is a Clinical Laboratory Improvement Act (CLIA)-certified anatomic pathology and molecular diagnostics lab with a national sales force serving urologists, gastroenterologists, dermatologists, gynecologists, and other subspecialty physicians. Founded in 2006, Predictive Biosciences is privately funded by Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures and New Enterprise Associates.

OnTarget, Inc. provides consulting services and training program for sales and consulting firm. The company is headquartered in Atlanta, GA.

Biotheranostics, Inc. develops and provides diagnostic, prognostic and predictive tests that support physicians in the treatment of cancer patients. It has commercialized two proprietary, highly differentiated products focused on early stage breast cancer and all metastatic cancers, Breast Cancer Index (BCI) and CancerTYPE ID (CTID). The company was founded by Thomas M. Baer in 2008 and is headquartered in San Diego, CA.

YourBio Health, Inc. develops health monitoring products. It is developing an array of products based on the company's proprietary TAP? (Touch Activated Phlebotomy) painless blood collection platform. The company was founded by Richard Rox Anderson, Joerg Lahann, Robert S. Langer Jr., Douglas A. Levinson and Samir Mitragotri in 2008 and is headquartered in Medford, MA.

Iquity Systems AB is a Swedish company that specializes in accelerating precision medicine. The private company is based in Stockholm, Sweden. The company's focus is on delivering the right patient with the right drug at the right time. The company was founded by Chase Spurlock and he has been the CEO since incorporation.

Iquity, Inc. is an American company that focuses on accelerating precision medicine. Iquity is based in Nashville. The private company's goal is to deliver the promise of precision medicine by ensuring that the right patient receives the right drug at the right time. The company recognizes that precision medicine is a complex process that requires connected data, mature, scalable data operations, and analytics expertise.

Stemina Biomarker Discovery, Inc. engages in the development and commercialization of molecular biomarkers to improve drug safety and human health. Its products and services include Cardio quickPredict, devTOX quickPredict, and TOXquickPredict. The company was founded by Elizabeth L. R. Donley and Gabriela G. Cezar in November 2006 and is headquartered in Madison, WI.

Geneoscopy LLC develops diagnostics It has developed a novel methodology to reliably and consistently extract human RNA transcripts from stool samples and detect changes in gene expression. The firm provides Geneoscopy a platform to harness the power of RNA to detect, prevent, and guide treatment for gastrointestinal disease. The company was founded by Andrew Barnell, Erica Barnell and Yiming Kang in 2015 and is headquartered in Saint Louis, MO.

Arima Genomics Inc. provides tools to help scientists accelerate. The firm offers Arima-HIC kit which helps in understanding of genome structure and sequence. The company was founded by Siddarth Selvara and is headquartered in San Diego, CA.

Breathe BioMedical, Inc. engages in the development of breath tests to detect early-state breast cancer. Its products include breath samplers and spectrometers. The company was founded by John Cormier on April 1, 2005 and is headquartered in Moncton, Canada.

Decode Health, Inc. is an American US-based health-tech company that provides a data platform to accelerate precision medicine and improve the efficiency of pharma research and development using AI and machine learning. The private company has partnered with leading research partners, diagnostic and technology companies to support pharma R & D. The company's goal is to deliver on the promise of precision medicine by connecting data and providing mature, scalable data operations and analytics expertise.

Part of Bioporto A/S, Bioporto Diagnostics A/S is a Danish company that engages in research and experimental development on biotechnology. The company is based in Gentofte, Denmark. Peter Morch Eriksen has been the CEO of the company since 2013.